Anti-cancer assays on a solid lung tumour or malignant pleural effusion model have shown that anti-MUC-1 CAR-Ms can be differentiated with a stable CD86+ TNF-α+ IL-8+ IL-1β+ M1 phenotype, displaying tumour-restricted phagocytosis and antigen-specific lysosomal processing with negligible off-target specificities (70). This evidence concerns the gene MUC1 and neoplasm.